Factors Associated With the Discontinuation of Two Short-Course Tuberculosis Preventive Therapies in Programmatic Settings in the United States

被引:0
作者
Asare-Baah, Michael [1 ,2 ]
Salmon-Trejo, LaTweika A. T. [3 ,4 ]
Venkatappa, Thara [5 ]
Garfein, Richard S. [6 ]
Aiona, Kaylynn [7 ]
Haas, Michelle [8 ]
Seraphin, Marie Nancy [2 ]
机构
[1] Univ Florida, Dept Epidemiol, Gainesville, FL USA
[2] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA
[3] Univ Florida, Dept Med, Div Infect Dis & Global Med, Gainesville, FL USA
[4] Florida A&M Univ, Inst Publ Hlth, Tallahassee, FL USA
[5] CDCP, Div TB Eliminat, Atlanta, GA USA
[6] Univ Calif San Diego, Herbert Wertheim Sch Publ Hlth, San Diego, CA USA
[7] Publ Hlth Inst Denver Hlth, Denver, CO USA
[8] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Denver, CO USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 06期
关键词
latent tuberculosis infection; preventive therapy; TB treatment; treatment adherence; tuberculosis; TREATMENT COMPLETION; DRUG-USE; INFECTION; RIFAPENTINE; REGIMEN; TRIAL;
D O I
10.1093/ofid/ofae313
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The objective of this study was to investigate timing and risk factors for discontinuation of short-course tuberculosis preventive therapy (TPT) comparing directly observed 3-month isoniazid/rifapentine (3HP) vs self-administered 4-month rifampin (4R). Methods This was a subanalysis of a 6-month health department cohort (2016-2017) of 993 latent tuberculosis infection (LTBI) patients initiating 3HP (20%) or 4R (80%). Time at risk of TPT discontinuation was compared across regimens. Risk factors were assessed using mixed-effects Cox models. Results Short-course TPT discontinuation was higher with 4R (31% vs 14%; P < .0001), though discontinuation timing was similar. Latino ethnicity (hazard ratio [HR], 1.80; 95% CI, 1.20-2.90) and adverse events (HR, 4.30; 95% CI, 2.60-7.30) increased 3HP discontinuation risk. Social-behavioral factors such as substance misuse (HR, 12.00; 95% CI, 2.20-69.00) and congregate living (HR, 21.00; 95% CI, 1.20-360.00) increased 4R discontinuation risk. Conclusions TPT discontinuation differed by regimen, with distinct risk factors. Addressing social determinants of health within TPT programs is critical to enhance completion rates and reduce TB disease risk in marginalized populations.
引用
收藏
页数:9
相关论文
共 31 条
[1]   The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis [J].
Alsdurf, Hannah ;
Hill, Philip C. ;
Matteelli, Alberto ;
Getahun, Haileyesus ;
Menzies, Dick .
LANCET INFECTIOUS DISEASES, 2016, 16 (11) :1269-1278
[2]   Changes in tuberculosis epidemiology, United States, 1993-2017 [J].
Armstrong, L. R. ;
Winston, C. A. ;
Stewart, B. ;
Tsang, C. A. ;
Langer, A. J. ;
Navin, T. R. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2019, 23 (07) :797-804
[3]  
Authority OH, 12-dose isoniazid (INH)/rifapentine regimen for treatment of latent TB infection (LTBI)
[4]   Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection [J].
Borisov, Andrey S. ;
Morris, Sapna Bamrah ;
Njie, Gibril J. ;
Winston, Carla A. ;
Burton, Deron ;
Goldberg, Stefan ;
Woodruff, Rachel Yelk ;
Allen, Leeanna ;
LoBue, Philip ;
Vernon, Andrew .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (25) :723-726
[5]  
COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935
[6]   Tuberculosis and Illicit Drug Use: Review and Update [J].
Deiss, Robert G. ;
Rodwell, Timothy C. ;
Garfein, Richard S. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :72-82
[7]   Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis [J].
Haas, Michelle K. ;
Aiona, Kaylynn ;
Erlandson, Kristine M. ;
Belknap, Robert W. .
CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) :E3459-E3467
[8]   Updates in the Treatment of Active and Latent Tuberculosis [J].
Haas, Michelle K. ;
Belknap, Robert W. .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 39 (03) :297-309
[9]  
Heyd Amber, 2021, PLOS Glob Public Health, V1, pe0000017, DOI 10.1371/journal.pgph.0000017
[10]   Latent tuberculous infection in the United States and Canada: who completes treatment and why? [J].
Hirsch-Moverman, Y. ;
Shrestha-Kuwahara, R. ;
Bethel, J. ;
Blumberg, H. M. ;
Venkatappa, T. K. ;
Horsburgh, C. R., Jr. ;
Colson, P. W. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (01) :31-38